Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 13/20 | 0.67 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.46 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6265589 | 0.93 | MAPK14 (0.62) | MAPK14NR2E3ALDH1A1HTT | |
| SCHEMBL6291906 | 0.86 | MAPK14 (0.65) | MAPK14NR2E3ALDH1A1HTTHSD17B10 | |
| SCHEMBL4178254 | 0.84 | ALDH1A1 (0.61) | MAPK14NR2E3ALDH1A1HTTHSD17B10 | |
| SCHEMBL6378489 | 0.83 | NPBWR1 (0.54) | MAPK14NR2E3ALDH1A1HTTHSD17B10 | |
| SCHEMBL6371703 | 0.81 | MAPK14 (0.59) | MAPK14NR2E3ALDH1A1HTTHSD17B10 | |
| SCHEMBL6370909 | 0.81 | MAPK14 (1.00) | MAPK14ALDH1A1HTT | |
| SCHEMBL4047300 | 0.79 | ALDH1A1 (0.54) | NR2E3ALDH1A1HTTHSD17B10PFKFB3 | |
| SCHEMBL6288420 | 0.78 | MAPK14 (1.00) | MAPK14ALDH1A1 | |
| SCHEMBL4470415 | 0.77 | MAPK14 (1.00) | MAPK14ALDH1A1HTT | |
| SCHEMBL6604659 | 0.77 | PFKFB3 (0.52) | NR2E3ALDH1A1HTTHSD17B10PFKFB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050256122-A1 | Substituted pyridazinones | PHARMACIA CORPORATION | 2005-11-17 | — | — | US | disclosed |
| WO-2005007632-A1 | SUBSTITUTED PYRIDAZINONES AS INHIBITORS OF P38 | PHARMACIA CORPORATION (US) | 2005-01-27 | — | — | WO | disclosed |
| US-20050020594-A1 | Substituted pyridazinones | PHARMACIA CORPORATION | 2005-01-27 | — | — | US | disclosed |
| EP-1470112-A1 | SUBSTITUTED PYRIDAZINONES AS INHIBITORS OF P38 | Pharmacia Corporation (US) | 2004-10-27 | — | — | EP | disclosed |
| US-20040142932-A1 | Substituted pyridazinones | PHARMACIA CORPORATION | 2004-07-22 | — | — | US | disclosed |
| WO-2003059891-A1 | SUBSTITUTED PYRIDAZINONES AS INHIBITORS OF P38 | PHARMACIA CORPORATION (US) | 2003-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142932-A1 | Substituted pyridazinones | MAP4K2, MAPK6, MAP3K6 | MAPK14 29/4885NR2E3 2748/4885ALDH1A1 1889/4885 |
| US-20050020594-A1 | Substituted pyridazinones | MAP4K2, MAPK6, MAP3K6 | MAPK14 34/4885NR2E3 2373/4885ALDH1A1 2217/4885 |
| US-20050256122-A1 | Substituted pyridazinones | MAP4K2, MAPK6, MAP3K6 | MAPK14 34/4885NR2E3 2373/4885ALDH1A1 2217/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.